Trial Profile
A randomized, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with familial dysbetalipoproteinemia
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Bezafibrate (Primary)
- Indications Hyperlipoproteinaemia type III
- Focus Therapeutic Use
- Acronyms EFFECT-FD
- 11 Jun 2015 New trial record